Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Moves into MicroRNA, Signs Preclinical Platform Deal with Regulus

This article was originally published in The Pink Sheet Daily

Executive Summary

With $25 million upfront, $10 million in equity and hundreds of millions of dollars in possible milestones, Sanofi makes a significant early bet on the latest RNA-based therapeutic class to emerge.

You may also be interested in...

MicroRNA Momentum Builds, But Will Big Pharma Embrace It?

While interest in microRNA may not be moving at the speed that some investors (and, certainly, some smaller companies) may like, Big Pharma has taken notice of the little oligos and is watching the sector.

AstraZeneca Taps Regulus For microRNA Drug Development

Alnylam/Isis spinout Regulus nabs two high-profile partners for its microRNA platform by signing an agreement with AstraZeneca that includes a $28 million upfront payment and equity investment, and a separate deal with Biogen Idec.

Sanofi Holds Brainstorming Sessions To Fuel Its Therapeutic Strategy Units

Just two years after Sanofi-Aventis SA set out to reinvent itself as the flexible, entrepreneurial, easy-partnering, globally diversified health care leader of the future, the French pharma has mounted a grassroots campaign to familiarize the academic/biotech community with its new Therapeutic Strategy Units, a handful of targeted areas with high unmet need and commensurately huge opportunity that are part of Sanofi's long-range R&D strategy.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts